- Policy
- MFDS to independently investigate data manipulation
- by Lee, Jeong-Hwan Jul 31, 2020 06:33am
- “This day in K-Bio is a hurdle we have to overcome to become the new drug developing country that tackles unmet medical needs. But we have already started working on creating fertile grounds to leverage the Korean-made pharmaceuticals in the global market by utilizing this hurdle as an opportunity to tighten administrative investigational p
- Company
- GC Pharma, applied for Phase II clinical trial of GC5131A
- by Kim, Jin-Gu Jul 31, 2020 06:31am
- GC Pharma announced on the 29th that it had applied to the MFDS for a clinical trial phase II plan for COVID-19 blood plasma tx, 'GC5131A'. Samsung Medical Center, Asan Medical Center, Chung-Ang University Hospital, Korea University Ansan Hospital, and Chungnam National University Hospital are targeting 60 people. 'GC5131A' is a Hyperi
- Policy
- “Primary care-based remote medicine as a supplement"
- by Lee, Jeong-Hwan Jul 30, 2020 06:20am
- To respond against novel infectious disease like COVID-19 and super-aged society, experts claim the South Korean society should prepare for an introduction to digital healthcare and remote medicine. In particular, the experts pointed out the remote medicine (non-contact medical care) would not replace the traditional medical care, but it
- Policy
- Biosimilars are growing at 52% among pharmaceutical exports
- by Lee, Hye-Kyung Jul 30, 2020 06:18am
- Pharmaceutical exports in the first half of this year were $3.8 billion, up 52.5% from the previous year's $2.5 billion. Biosimilars account for 52% of export items ($1.98 billion). he KHIDI (Director, Deok-cheol Kwon) held a press conference at 11:00 am on the 29th and announced major performance trends such as health industry exports, jo
- Company
- Big 5 green lit another CDK4/6 inhibitor Verzenio
- by Eo, Yun-Ho Jul 30, 2020 06:18am
- General hospitals in South Korea are entering prescription code for anticancer treatment Verzenio. According to pharmaceutical industry sources on July 28, drug committees at the Big Fives including Seoul National University Hospital, Severance Hospital and Samsung Medical Center, and other major general hospitals like National Cancer Cen
- Policy
- NECA, the safety and effectiveness of Epidyolex & Sativex
- by Lee, Hye-Kyung Jul 30, 2020 06:17am
- The NECA announced on the 28th that it has drawn the first social consensus on the safety and effectiveness of Epidyolex and Sativex, a hemp-derived drug approved in Korea. Recently, With Byung-Joo Park, Professor of the Department of Preventive Medicine, Seoul National University, Young-Chul Kang, Professor of Department of Pediatrics, Sever
- Policy
- Nesp, cheaper than biosimilar due to voluntary price cut
- by Lee, Tak-Sun Jul 29, 2020 09:45pm
- The second-generation EPO 'Nesp' (Darbepoetin alfa/Kyowa Kirin, Korea) has become cheaper than biosimilar through voluntary cuts in insurance premiums. According to the MOHW, as of August 1st, Nesp cut its insurance upper limit by 12.5% for each dose. Accordingly, in the case of Nesp PFS 20, it was lowered from \19,898 to \17,411. Last
- Company
- 2,000 reimbursed items were registered for 3 months
- by Chon, Seung-Hyun Jul 29, 2020 06:34am
- Pharmaceuticals have launched generic products enormously ahead of the new drug price system. In the last three months, about 2000 generics have been licensed and listed. It is to receive upper limit price before applying cascading drug price system that the later it is registered, the lower the price. The government's restrictions on generics h
- Company
- HCV drug Mavyret prescription goes down by 31% amid COVID-19
- by Kim, Jin-Gu Jul 29, 2020 06:33am
- Although Mavyret (glecaprevir) dominated the hepatitis C treatment market as soon as it was launched, the treatment took a steep fall in prescription volume. The pharmaceutical industry sources argue the 31-percent drop compared to last year would have been impacted by decreased number of patients and COVID-19. According to the pharmace
- Company
- Eight generic companies for Lixiana are expected to compete
- by Kim, Jin-Gu Jul 29, 2020 06:31am
- Hanmi and Boryung overcome the patent of oral anticoagulant (NOAC) 'Lixiana' (Edoxaban). Eight generic companies, including those, are expected to compete after the patent expires in November 2026. The Intellectual Property Trial and Appeal Board recently decided on 'claims established'' at a trial to confirm the passive scope of rights
